ACL.AU Australian Clinical Labs Ltd
- Market cap
- AUD 616M
- P/E
- 27.5x
- P/B
- 4.12x
- ROE
- 15.9%
- Dividend yield
- 4.00%
- Fundamental score
- 1.4/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ACL.AU undervalued?
Graham numberACL.AU trades 124.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Australian Clinical Labs Ltd fundamental analysis
7 of 22 checks passedROE 1/2
Moderate return on equity (15.9%), between 10% and 20%.
ROA 1/1
Return on assets (4.0%) is above the industry median (-0.3%).
Profit Consistency 2/2
Profitable for 7 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-27.7%) is not above the 5-year average (-20.9% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-27.7%) is below the industry median (-1.5%).
Revenue Growth 1/2
Revenue grew 1.8% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (225.7%), above 100%.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is 3.3x against interest expense, below 5x.
PE vs Market 0/1
PE (27.5x) is above the market median (15.0x).
PE vs Industry 0/1
PE (27.5x) is above the industry median (27.1x).
PBV 0/1
Price to book (4.1x) is above the industry median (2.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 113.2, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (4.0%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
Payout ratio is 103.7%, above 90% of earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Australian Clinical Labs Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Australian Clinical Labs Ltd
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers cardiac testing, gastroenterology, haematology, chemical pathology, antenatal testing, serology and microbiology, cervical screening, commercial drug and alcohol testing, STI Testing, veterinary pathology, molecular cancer services, clinical trials pathology, advanced genetic testing, functional pathology, histopathology and cytopathology, CPD education programs for clini…
Full company profileAustralian Clinical Labs Ltd financial statements
Australian Clinical Labs Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 340M | 376M | 446M | 488M | 641M | 989M | 692M | 690M | 741M | 730M |
| Gross Profit | 282M | 110M | 132M | 85.0M | 522M | 782M | 566M | 138M | 271M | 150M |
| Operating Income | -20.6M | -5.91M | -7.58M | 15.5M | 123M | 268M | 56.1M | 56.9M | 271M | 61.5M |
| EBITDA | -8.06M | 5.41M | 19.3M | 108M | 197M | 373M | 185M | 170M | 204M | 197M |
| Net Income | -24.0M | -9.01M | -10.5M | 41.3M | 60.4M | 178M | 35.9M | 23.9M | 32.4M | 23.7M |
| EPS | -0.12 | -0.04 | -0.05 | 0.20 | 0.40 | 0.88 | 0.18 | 0.12 | 0.17 | 0.12 |
| Balance Sheet | ||||||||||
| Total Assets | 121M | 119M | 154M | 366M | 475M | 628M | 579M | 593M | 575M | 593M |
| Total Liabilities | 107M | 114M | 126M | 297M | 393M | 395M | 406M | 415M | 403M | 443M |
| Shareholders' Equity | 14.1M | 5.46M | 27.4M | 69.0M | 81.9M | 232M | 172M | 178M | 171M | 150M |
| Cash & Short-term Investments | 7.34M | 9.78M | 5.13M | 35.3M | 36.3M | 27.5M | 20.6M | 26.8M | 22.1M | 25.7M |
| Total Debt | 48.3M | 53.5M | 56.0M | 221M | 294M | 262M | 316M | 309M | 290M | 337M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 4.60M | 4.69M | 1.11M | 102M | 154M | 284M | 144M | 160M | 183M | 163M |
| Capital Expenditure | 7.46M | 8.64M | 14.4M | 9.38M | 9.51M | 21.3M | 6.93M | 6.51M | 8.41M | 9.58M |
| Free Cash Flow | -2.86M | -3.94M | -13.3M | 92.4M | 144M | 263M | 137M | 153M | 174M | 154M |
| Ratios | ||||||||||
| ROE | -170.2% | -165.1% | -38.4% | 59.8% | 73.7% | 76.7% | 20.8% | 13.5% | 18.9% | 15.9% |
| ROA | -19.9% | -7.6% | -6.9% | 11.3% | 12.7% | 28.4% | 6.2% | 4.0% | 5.6% | 4.0% |
| Net Profit Margin | -7.1% | -2.4% | -2.4% | 8.5% | 9.4% | 18.0% | 5.2% | 3.5% | 4.4% | 3.3% |
| Debt to Equity | 3.42x | 9.81x | 2.04x | 3.21x | 3.59x | 1.13x | 1.83x | 1.74x | 1.69x | 2.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Australian Clinical Labs Ltd dividends
- Dividend yield
- 4.00%
- Forward dividend
- 0.13 AUD
- Payout ratio
- 103.7%
- Ex-dividend date
- Sep 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 24.6M | 0.13 | 103.7% |
| 2025 | AUD 24.9M | 0.13 | 76.9% |
| 2024 | AUD 19.9M | 0.10 | 83.4% |
| 2023 | AUD 96.9M | 0.48 | 269.9% |
| 2022 | AUD 24.2M | 0.12 | 13.6% |
| 2021 | 42.0M | 0.28 | 69.6% |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Australian Clinical Labs Ltd
- Insiders 3.56%
- Institutions 90.30%
- Public & others 6.13%
- Shares outstanding 187M
- Free float 168M
Australian Clinical Labs Ltd company profile
- Company name
- Australian Clinical Labs Ltd
- Ticker
- ACL.AU
- ISIN
- AU0000148496
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 4,500
- Fiscal year end
- June
- Address
- 1868-1892 Dandenong Road, Clayton, VIC, Australia, 3168
- Phone
- 61 1300 453 688
- Website
- clinicallabs.com.au
About Australian Clinical Labs Ltd
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers cardiac testing, gastroenterology, haematology, chemical pathology, antenatal testing, serology and microbiology, cervical screening, commercial drug and alcohol testing, STI Testing, veterinary pathology, molecular cancer services, clinical trials pathology, advanced genetic testing, functional pathology, histopathology and cytopathology, CPD education programs for clinicians, and allergy and immunology services. It also provides workplace services, environmental screening, and clinical trial services. The company offers its services under the SunDoctors, SouthernSun Pathology, Specialised Trials, BeFunctional Labs, and Gribbles Veterinary Pathology brands. It serves doctors, patients, and corporate clients. The company was founded in 2015 and is headquartered in Clayton, Australia.
Australian Clinical Labs Ltd management
9- Mr. Gregory John HoranGroup CEO, MD & Executive Director
- Mr. Anthony FriedliChief Operating Officer
- Mr. Sean JacksonChief Information Officer
- Mr. Joe GeranNational Marketing Director
- Associate Prof. Tony LandgrenNational Medical Director & Chief Pathologist
- Mr. Chris BrownlowChief Executive Officer of New South Wales & Australian Capital Territory
- Ms. Shae SeymourChief Risk Officer & CEO of WA/SA/NT
- Ms. Eleanor Padman B.A., FCISCompany Secretary
- Mr. Darren McKeeChief Executive Officer of Victoria